Early Discovery Optimization
Transform Screening Hits into Drug-Like Lead Compounds.
Rapid, data-driven hit-to-lead optimization designed to identify the most viable paths forward early.
Early discovery decisions define downstream success. GD3 helps you quickly distinguish true opportunities from false positives, ensuring resources are focused on chemistry with real clinical potential.
Our hit-to-lead approach balances speed, scientific rigor, and risk management, enabling confident progression into lead optimization.
Services Overview
- Hit confirmation through re-synthesis and purification
- Initial SAR analysis and chemical liability assessment (including PAINS)
- Hit expansion via focused analog design and synthesis
- Preliminary in vitro ADME profiling
- Data-driven selection of 2–3 optimized lead series
